Immediate Impact
52 standout
Citing Papers
Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy
2024 Standout
HER2-targeted therapies in cancer: a systematic review
2024 Standout
Works of Kemal Balic being referenced
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
2021
MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Kemal Balic | 91 | 57 | 19 | 97 | 13 | 179 | |
| Dingwei Ye | 54 | 77 | 5 | 137 | 12 | 194 | |
| Jonathon Golas | 43 | 138 | 5 | 125 | 11 | 257 | |
| Yuyang Tian | 21 | 121 | 16 | 109 | 18 | 273 | |
| Rui An | 30 | 148 | 4 | 76 | 16 | 258 | |
| Sara Neyt | 81 | 50 | 4 | 101 | 18 | 265 | |
| Enyuan Cao | 6 | 52 | 5 | 79 | 18 | 213 | |
| Hetal Sarvaiya | 45 | 49 | 4 | 67 | 16 | 115 | |
| D. Jette | 68 | 43 | 7 | 12 | 11 | 135 | |
| Ying Sun | 50 | 65 | 3 | 61 | 21 | 197 | |
| Kazumasa Sekihara | 26 | 130 | 10 | 30 | 13 | 207 |
All Works
Loading papers...